

LETTER

Safety and adverse events following COVID-19 vaccination and epilepsy: Correspondence

Dear Editor,

We would like to discuss “Safety and Adverse Events Following COVID-19 Vaccination among People with Epilepsy: A Cross-Sectional Study.”¹ The COVID-19 vaccination is safe for PWE, according to Ong et al. Following COVID-19 immunization, AEFI among PWE are comparable to those in the general population; thus, doctors should advise their PWE patients to receive COVID-19. Co-morbidity might be challenging to manage, so it is crucial to look at any potential COVID-19 vaccine problems.² This is frequently not an option if a clinical problem arises after the vaccination. It is imperative to screen out any underlying diseases or likely co-morbidities that could lead to a clinical problem before vaccination. There is still a chance that SARS-Co-V2 patients go undetected and show no symptoms. Co-morbidity is occasionally mistakenly thought to have a detrimental effect, and other sources are easily misconstrued.³ Recent studies⁴ have also connected underlying genetic variation to recipients' immune responses to the COVID-19 vaccine. Future studies should consider the many genetic background elements that might relate to reaction to the vaccine.

CONFLICT OF INTEREST

Neither of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. You will find our policy on ethical publication in our instructions for authors.

Rujittika Mungmunpantipantip¹ 
Viroj Wiwanitkit²

¹Private Academic Consultant, Bangkok, Thailand
²Department of Pharmaceutical Sciences, University Centre for Research & Development, Chandigarh University, Mohali, India

Correspondence

Rujittika Mungmunpantipantip, Private Academic Consultant, Bangkok, Thailand.
Email: rujittika@gmail.com

ORCID

Rujittika Mungmunpantipantip  <https://orcid.org/0000-0003-0078-7897>

REFERENCES

1. Ong MJY, Khoo CS, Lee YX, Poongkuntran V, Tang CK, Choong YJ, et al. Safety and adverse events following COVID-19 vaccination among people with epilepsy: a cross-sectional study. *Epilepsia Open*. 2022. <https://doi.org/10.1002/epi4.12658>
2. Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. *J Prev Med Public Health*. 2020;53(2):70.
3. Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. *Clin Appl Thromb Hemost*. 2021;27:10760296211047229.
4. Čiučiulkaitė I, Möhlendick B, Thümmler L, Fisenkci N, Elsner C, Dittmer U, et al. GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. *Front Genet*. 2022;13:932043.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *Epilepsia Open* published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.